<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00316524</url>
  </required_header>
  <id_info>
    <org_study_id>POX-MVA-005</org_study_id>
    <secondary_id>DMID 05-0128</secondary_id>
    <secondary_id>EudraCT No. 2005-001781-14</secondary_id>
    <nct_id>NCT00316524</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-blind, Placebo-controlled Study on Immunogenicity and Safety of MVA-BN (IMVAMUNE™) Smallpox Vaccine in Healthy Subjects</brief_title>
  <official_title>A Partially Randomized, Partially Double-blind, Placebo-controlled Phase II Non-inferiority Study to Evaluate Immunogenicity and Safety of One and Two Doses of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in 18-55 Year Old Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bavarian Nordic</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Bavarian Nordic</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the immune response after a single
      vaccination of pre-immune subjects compared to two vaccinations in naive subjects.

      In addition the study further investigates the cardiac safety profile of MVA-BN® in a healthy
      population compared to placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of 4 groups, which receive either MVA-BN once, MVA-BN two times, MVA-BN
      followed by placebo, or two administrations of placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2006</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Seroconversion by ELISA</measure>
    <time_frame>2 weeks following the last vaccination (Week 6 for Groups 1-3, Week 2 for Group 4)</time_frame>
    <description>Seroconversion rate based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA). Seroconversion is defined as the appearance of antibody titers ≥ detection limit (50) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With ECG Changes</measure>
    <time_frame>within 2 weeks after each vaccination</time_frame>
    <description>Occurrence of any specific or unspecific ECG change. Assessments at Screening (SCR), Visit 2 (Week 2) and Visit 4 (Week 6).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Cardiac Adverse Events (Adverse Events of Special Interest [AESI])</measure>
    <time_frame>within 32 weeks</time_frame>
    <description>Occurrence and relationship of any other cardiac symptom at any time during the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroconversion by ELISA</measure>
    <time_frame>4 weeks following the last vaccination (Week 8 for Groups 1-3, Week 4 for Group 4)</time_frame>
    <description>Seroconversion rate based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA). Seroconversion is defined as the appearance of antibody titers ≥ detection limit (50) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroconversion by PRNT</measure>
    <time_frame>2 weeks following the last vaccination (Week 6 for Groups 1-3, Week 2 for Group 4)</time_frame>
    <description>Seroconversion rate based on vaccinia-specific Plaque Reduction Neutralization Test (PRNT). Seroconversion is defined as the appearance of antibody titers ≥ detection limit (6) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroconversion by PRNT</measure>
    <time_frame>4 weeks following the last vaccination (Week 8 for Groups 1-3, Week 4 for Group 4)</time_frame>
    <description>Seroconversion rate based on vaccinia-specific Plaque Reduction Neutralization Test (PRNT). Seroconversion is defined as the appearance of antibody titers ≥ detection limit (6) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Related Serious Adverse Events</measure>
    <time_frame>within 32 weeks</time_frame>
    <description>Number of participants with any serious adverse event possibly, probably or definitely related to the study vaccine at any time during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Solicited Local Adverse Events</measure>
    <time_frame>within 8 days after any vaccination</time_frame>
    <description>Number of participants with solicited local AEs (pain, erythema, swelling and induration) within 8 days after any vaccination (vaccinations for Groups 1-3: Days 0 and 28; Group 4: Day 0). Percentages based on subjects with at least one completed diary card.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Solicited General Adverse Events</measure>
    <time_frame>within 8 days after any vaccination</time_frame>
    <description>Number of participants with solicited systemic/general AEs (body temperature increased, headache, myalgia, nausea, and fatigue) within 8 days after any vaccination (vaccinations for Groups 1-3: Days 0 and 28; Group 4: Day 0). Percentages based on subjects with at least one completed diary card.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Related Grade&gt;=3 Adverse Events</measure>
    <time_frame>within 4 weeks after any vaccination</time_frame>
    <description>Number of participants with any Grade &gt;=3 AE probably, possibly, or definitely related to the study vaccine within 4 weeks after any vaccination (vaccinations for Groups 1-3: Days 0 and 28; Group 4: Day 0). Pooled solicited (local and general) and unsolicited AEs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Unsolicited Non-serious Adverse Events</measure>
    <time_frame>within 4 weeks after any vaccination</time_frame>
    <description>Number of participants with non-serious unsolicited AEs within 4 weeks after any vaccination (vaccinations for Groups 1-3: Days 0 and 28; Group 4: Day 0).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">745</enrollment>
  <condition>Smallpox</condition>
  <arm_group>
    <arm_group_label>GP 1: two x 1x10E08 TCID, MVA-BN® s.c., vaccinia naive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vaccinia naive subjects receiving two subcutanenous vaccinations with 0.5ml MVA-BN® IMVAMUNE (1x10E08 TCID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GP 2: 1x10E08 TCID, MVA-BN®, 1x Placebo, s.c., vaccinia naive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vaccinica naive subjects receiving one vaccination with 0.5ml MVA-BN® IMVAMUNE(1x10E08 TCID), followed by one vaccination Placebo (0.5ml Tris Buffer)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GP 3: two x Placebo, s.c., vaccinia naive</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>vaccinia naive subjects, receiving two subcutaneous vaccinations with Placebo (0.5ml Tris Buffer).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GP 4: 1x10E08 TCID, MVA-BN®, s.c., vaccinia experienced</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vaccinia experienced subjects, receiving one subcutaneous vaccination with 0.5ml MVA-BN® IMVAMUNE (1x10E08 TCID).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA-BN® (IMVAMUNE)</intervention_name>
    <description>1x 10E8_TCID50</description>
    <arm_group_label>GP 1: two x 1x10E08 TCID, MVA-BN® s.c., vaccinia naive</arm_group_label>
    <arm_group_label>GP 2: 1x10E08 TCID, MVA-BN®, 1x Placebo, s.c., vaccinia naive</arm_group_label>
    <arm_group_label>GP 4: 1x10E08 TCID, MVA-BN®, s.c., vaccinia experienced</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tris-Buffer</description>
    <arm_group_label>GP 2: 1x10E08 TCID, MVA-BN®, 1x Placebo, s.c., vaccinia naive</arm_group_label>
    <arm_group_label>GP 3: two x Placebo, s.c., vaccinia naive</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female subjects between 18 and 55 years of age.

          2. Women must have a negative serum pregnancy test at screening and a negative urine or
             serum pregnancy test within 24 hours prior to vaccination.

          3. Women of childbearing potential must have used an acceptable method of contraception
             for 30 days prior to the first vaccination, must agree to use an acceptable method of
             contraception during the study, and must not become pregnant for at least 28 days
             after the last vaccination. A woman is considered of childbearing potential unless
             post-menopausal or surgically sterilized. (Acceptable contraception methods are
             restricted to abstinence, barrier contraceptives, intrauterine contraceptive devices
             or licensed hormonal products.)

          4. Lab values without clinically significant findings

          5. Electrocardiogram (ECG) without abnormal findings (e.g. any kind of atrioventricular
             or intraventricular conditions or blocks such as complete left or right bundle branch
             block, AV-node block, QTc or PR prolongation, premature atrial contractions or other
             atrial arrhythmia, sustained ventricular arrhythmia, 2 premature ventricular
             contractions (PVC) in a row, ST elevation consistent with ischemia).

        Groups 1, 2 and 3 (All vaccinia-naïve subjects) additionally:

          1. No history of known or suspected previous smallpox vaccination.

          2. No detectable vaccinia scar.

        Group 4 (All previously vaccinated subjects) additionally:

          1. History of previous smallpox vaccination (documented and/or typical vaccinia scar).

          2. Most recent smallpox vaccination ≥ 5 years.

        Exclusion Criteria:

          1. Uncontrolled serious infection i.e. not responding to antimicrobial therapy.

          2. History of or active autoimmune disease. Persons with vitiligo or thyroid disease
             taking thyroid replacement are not excluded.

          3. Known or suspected impairment of immunologic function including, but not limited to,
             clinically significant liver disease; diabetes mellitus; moderate to severe kidney
             impairment.

          4. History of malignancy, other than squamous cell or basal cell skin cancer, unless
             there has been surgical excision that is considered to have achieved cure. Subjects
             with history of skin cancer at the vaccination site are excluded.

          5. History of coronary heart disease, myocardial infarction, angina, congestive heart
             failure, cardiomyopathy, stroke or transient ischemic attack, uncontrolled high blood
             pressure, or any other heart condition under the care of a doctor.

          6. History of an immediate family member (father, mother, brother, or sister) who died
             due to ischemic heart disease before age 50 years.

          7. Ten percent or greater risk of developing a myocardial infarction or coronary death
             within the next 10 years using the National Cholesterol Education Program's risk
             assessment tool. (http://hin.nhlbi.nih.gov/atpiii/calculator.asp?usertype=prof) NOTE:
             This criterion applies only to volunteers 20 years of age and older.

          8. History of anaphylaxis or severe allergic reaction.

          9. Immune modulatory therapy.

         10. History of any serious medical condition, which in the opinion of the investigator
             would compromise the safety of the subject.

         11. History or clinical manifestation of clinically significant and severe hematological,
             renal, hepatic, pulmonary, central nervous, cardiovascular or gastrointestinal
             disorders.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank von Sonnenburg, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Section of International Medicine &amp; Public Health, Department of Infectious Diseases and Tropical Medicine, Ludwig-Maximilians Unviersity Munich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Harrison Clinical Research GmbH</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Zitzmann-Roth EM, von Sonnenburg F, de la Motte S, Arndtz-Wiedemann N, von Krempelhuber A, Uebler N, Vollmar J, Virgin G, Chaplin P. Cardiac safety of Modified Vaccinia Ankara for vaccination against smallpox in a young, healthy study population. PLoS One. 2015 Apr 16;10(4):e0122653. doi: 10.1371/journal.pone.0122653. eCollection 2015.</citation>
    <PMID>25879867</PMID>
  </results_reference>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>April 19, 2006</study_first_submitted>
  <study_first_submitted_qc>April 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2006</study_first_posted>
  <results_first_submitted>December 19, 2018</results_first_submitted>
  <results_first_submitted_qc>December 19, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 9, 2019</results_first_posted>
  <last_update_submitted>February 11, 2019</last_update_submitted>
  <last_update_submitted_qc>February 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Smallpox</keyword>
  <keyword>Vaccination</keyword>
  <keyword>Prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Smallpox</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1: 2 x MVA-BN® s.c., Vaccinia Naive</title>
          <description>vaccinia naive subjects receiving two subcutaneous vaccinations with 0.5mL MVA-BN® IMVAMUNE (1x10E08 TCID50)</description>
        </group>
        <group group_id="P2">
          <title>Group 2: 1x MVA-BN®, 1x Placebo, s.c., Vaccinia Naive</title>
          <description>vaccinia naive subjects receiving one subcutaneous vaccination with 0.5mL MVA-BN® IMVAMUNE (1x10E08 TCID50), followed by one vaccination Placebo (0.5mL Tris Buffer)</description>
        </group>
        <group group_id="P3">
          <title>Group 3: Two x Placebo, s.c., Vaccinia Naive</title>
          <description>vaccinia naive subjects receiving two subcutaneous vaccinations with Placebo (0.5mL Tris Buffer).
Placebo: Tris-Buffer</description>
        </group>
        <group group_id="P4">
          <title>Group 4: 1x MVA-BN®, s.c., Vaccinia Experienced</title>
          <description>vaccinia experienced subjects receiving one subcutaneous vaccination with 0.5ml MVA-BN® IMVAMUNE (1x10E08 TCID50).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="183"/>
                <participants group_id="P2" count="181"/>
                <participants group_id="P3" count="181"/>
                <participants group_id="P4" count="200"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="175"/>
                <participants group_id="P2" count="173"/>
                <participants group_id="P3" count="175"/>
                <participants group_id="P4" count="200"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Dataset</population>
      <group_list>
        <group group_id="B1">
          <title>Group 1: 2x MVA-BN® s.c., Vaccinia Naive</title>
          <description>vaccinia naive subjects receiving two subcutaneous vaccinations with 0.5mL MVA-BN® IMVAMUNE (1x10E08 TCID50)</description>
        </group>
        <group group_id="B2">
          <title>Group 2: 1x MVA-BN®, 1x Placebo, s.c., Vaccinia Naive</title>
          <description>vaccinia naive subjects receiving one subcutaneous vaccination with 0.5mL MVA-BN® IMVAMUNE (1x10E08 TCID50), followed by one vaccination Placebo (0.5mL Tris Buffer)</description>
        </group>
        <group group_id="B3">
          <title>Group 3: 2x Placebo, s.c., Vaccinia Naive</title>
          <description>vaccinia naive subjects receiving two subcutaneous vaccinations with Placebo (0.5mL Tris Buffer)
Placebo: Tris-Buffer</description>
        </group>
        <group group_id="B4">
          <title>Group 4: 1x MVA-BN®, s.c., Vaccinia Experienced</title>
          <description>vaccinia experienced subjects receiving one subcutaneous vaccination with 0.5mL MVA-BN® IMVAMUNE (1x10E08 TCID50)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="183"/>
            <count group_id="B2" value="181"/>
            <count group_id="B3" value="181"/>
            <count group_id="B4" value="200"/>
            <count group_id="B5" value="745"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.3" spread="4.98"/>
                    <measurement group_id="B2" value="25.4" spread="4.38"/>
                    <measurement group_id="B3" value="26.0" spread="5.1"/>
                    <measurement group_id="B4" value="41.5" spread="7.59"/>
                    <measurement group_id="B5" value="29.8" spread="9.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="112"/>
                    <measurement group_id="B3" value="107"/>
                    <measurement group_id="B4" value="115"/>
                    <measurement group_id="B5" value="431"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="74"/>
                    <measurement group_id="B4" value="85"/>
                    <measurement group_id="B5" value="314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Ethnic group</title>
              <category_list>
                <category>
                  <title>Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="178"/>
                    <measurement group_id="B2" value="176"/>
                    <measurement group_id="B3" value="177"/>
                    <measurement group_id="B4" value="198"/>
                    <measurement group_id="B5" value="729"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Arabic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="183"/>
                    <measurement group_id="B2" value="181"/>
                    <measurement group_id="B3" value="181"/>
                    <measurement group_id="B4" value="200"/>
                    <measurement group_id="B5" value="745"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Seroconversion by ELISA</title>
        <description>Seroconversion rate based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA). Seroconversion is defined as the appearance of antibody titers ≥ detection limit (50) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
        <time_frame>2 weeks following the last vaccination (Week 6 for Groups 1-3, Week 2 for Group 4)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>GP 1: Two x 1x10E08 TCID, MVA-BN® s.c., Vaccinia Naive</title>
            <description>vaccinia naive subjects receiving two subcutaneous vaccinations with 0.5ml MVA-BN® IMVAMUNE (1x10E08 TCID)
MVA-BN® (IMVAMUNE): 1x 10E8_TCID50</description>
          </group>
          <group group_id="O2">
            <title>GP 2: 1x10E08 TCID, MVA-BN®, 1x Placebo, s.c., Vaccinia Naive</title>
            <description>vaccinia naive subjects receiving one subcutaneous vaccination with 0.5ml MVA-BN® IMVAMUNE (1x10E08 TCID), followed by one subcutaneous vaccination Placebo (0.5ml Tris Buffer)
MVA-BN® (IMVAMUNE): 1x 10E8_TCID50
Placebo: Tris-Buffer</description>
          </group>
          <group group_id="O3">
            <title>GP 3: Two x Placebo, s.c., Vaccinia Naive</title>
            <description>vaccinia naive subjects receiving two subcutaneous vaccinations with Placebo (0.5ml Tris Buffer)
Placebo: Tris-Buffer</description>
          </group>
          <group group_id="O4">
            <title>GP 4: 1x10E08 TCID, MVA-BN®, s.c., Vaccinia Experienced</title>
            <description>vaccinia experienced subjects receiving one subcutaneous vaccination with 0.5ml MVA-BN® IMVAMUNE (1x10E08 TCID)
MVA-BN® (IMVAMUNE): 1x 10E8_TCID50</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion by ELISA</title>
          <description>Seroconversion rate based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA). Seroconversion is defined as the appearance of antibody titers ≥ detection limit (50) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
          <population>Full Analysis Set</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="174"/>
                <count group_id="O3" value="175"/>
                <count group_id="O4" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.9" lower_limit="96.0" upper_limit="99.9"/>
                    <measurement group_id="O2" value="82.2" lower_limit="75.7" upper_limit="87.6"/>
                    <measurement group_id="O3" value="3.4" lower_limit="1.3" upper_limit="7.3"/>
                    <measurement group_id="O4" value="95.5" lower_limit="91.6" upper_limit="97.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority margin to show that Group 4 (vaccinia experienced subjects receiving a single vaccination) is non-inferior to Group 1 (vaccinia naive subjects receiving 2 vaccinations) in terms of seroconversion rate 2 weeks after the last vaccination was predefined as -5% for the difference in seroconversion rates</non_inferiority_desc>
            <param_type>Difference in seroconversion rates (%)</param_type>
            <param_value>-3.4</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>-7.36</ci_lower_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With ECG Changes</title>
        <description>Occurrence of any specific or unspecific ECG change. Assessments at Screening (SCR), Visit 2 (Week 2) and Visit 4 (Week 6).</description>
        <time_frame>within 2 weeks after each vaccination</time_frame>
        <population>Safety dataset</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 2x MVA-BN® s.c., Vaccinia Naive</title>
            <description>vaccinia naive subjects receiving two subcutaneous vaccinations with 0.5mL MVA-BN® IMVAMUNE (1x10E08 TCID50)</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 1x MVA-BN®, 1x Placebo, s.c., Vaccinia Naive</title>
            <description>vaccinia naive subjects receiving one subcutaneous vaccination with 0.5mL MVA-BN® IMVAMUNE (1x10E08 TCID50), followed by one subcutaneous vaccination Placebo (0.5mL Tris Buffer)</description>
          </group>
          <group group_id="O3">
            <title>Group 3: 2x Placebo, s.c., Vaccinia Naive</title>
            <description>vaccinia naive subjects receiving two subcutaneous vaccinations with Placebo (0.5mL Tris Buffer)
Placebo: Tris-Buffer</description>
          </group>
          <group group_id="O4">
            <title>Group 4: 1x MVA-BN®, s.c., Vaccinia Experienced</title>
            <description>vaccinia experienced subjects receiving one subcutaneous vaccination with 0.5mL MVA-BN® IMVAMUNE (1x10E08 TCID50)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With ECG Changes</title>
          <description>Occurrence of any specific or unspecific ECG change. Assessments at Screening (SCR), Visit 2 (Week 2) and Visit 4 (Week 6).</description>
          <population>Safety dataset</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="181"/>
                <count group_id="O3" value="181"/>
                <count group_id="O4" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SCR : Supraventricular arrhytmia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR : Ventricular arrhythmia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR : AV block (PQ time &gt;0.20 sec) 1st degree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR : Right bundle branch block - incomplete</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR : ST elevation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR : ST depression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR : T inversion - pathological</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="50"/>
                    <measurement group_id="O4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR : T inversion - other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR : Low voltage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR : Other non-specific changes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR : Bradycardia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR : Arrhythmia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR : Repolarisation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR : Q-Abnormalities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCR : Tall T-waves</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 : Supraventricular arrhytmia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 : Ventricular arrhythmia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 : AV block (PQ time &gt;0.20 sec) 1st degree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 : Right bundle branch block - incomplete</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 : ST elevation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 : ST depression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 : T inversion - pathological</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="40"/>
                    <measurement group_id="O4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 : T inversion - other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 : Low voltage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 : Other non-specific changes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 : Bradycardia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 : Arrhythmia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 : Repolarisation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 : Q-Abnormalities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 : Tall T-waves</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 : Supraventricular arrhytmia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="NA">Visit not applicable to Group 4 subjects</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 : Ventricular arrhythmia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="NA">Visit not applicable to Group 4 subjects</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 : AV block (PQ time &gt;0.20 sec) 1st degree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="NA">Visit not applicable to Group 4 subjects</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 : Right bundle branch block - incomplete</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="NA">Visit not applicable to Group 4 subjects</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 : ST elevation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="NA">Visit not applicable to Group 4 subjects</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 : ST depression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="NA">Visit not applicable to Group 4 subjects</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 : T inversion - pathological</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="NA">Visit not applicable to Group 4 subjects</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 : T inversion - other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="NA">Visit not applicable to Group 4 subjects</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 : Low voltage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="NA">Visit not applicable to Group 4 subjects</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 : Other non-specific changes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="NA">Visit not applicable to Group 4 subjects</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 : Bradycardia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="NA">Visit not applicable to Group 4 subjects</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 : Arrhythmia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="NA">Visit not applicable to Group 4 subjects</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 : Repolarisation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="NA">Visit not applicable to Group 4 subjects</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 : Q-Abnormalities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="NA">Visit not applicable to Group 4 subjects</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 : Tall T-waves</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="NA">Visit not applicable to Group 4 subjects</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Cardiac Adverse Events (Adverse Events of Special Interest [AESI])</title>
        <description>Occurrence and relationship of any other cardiac symptom at any time during the study</description>
        <time_frame>within 32 weeks</time_frame>
        <population>Safety dataset</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 2x MVA-BN® s.c., Vaccinia Naive</title>
            <description>vaccinia naive subjects receiving two subcutaneous vaccinations with 0.5mL MVA-BN® IMVAMUNE (1x10E08 TCID50)</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 1x MVA-BN®, 1x Placebo, s.c., Vaccinia Naive</title>
            <description>vaccinia naive subjects receiving one subcutaneous vaccination with 0.5mL MVA-BN® IMVAMUNE (1x10E08 TCID50), followed by one subcutaneous vaccination Placebo (0.5mL Tris Buffer)</description>
          </group>
          <group group_id="O3">
            <title>Group 3: 2x Placebo, s.c., Vaccinia Naive</title>
            <description>vaccinia naive subjects receiving two subcutaneous vaccinations with Placebo (0.5mL Tris Buffer)
Placebo: Tris-Buffer</description>
          </group>
          <group group_id="O4">
            <title>Group 4: 1x MVA-BN®, s.c., Vaccinia Experienced</title>
            <description>vaccinia experienced subjects receiving one subcutaneous vaccination with 0.5mL MVA-BN® IMVAMUNE (1x10E08 TCID50)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Cardiac Adverse Events (Adverse Events of Special Interest [AESI])</title>
          <description>Occurrence and relationship of any other cardiac symptom at any time during the study</description>
          <population>Safety dataset</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="181"/>
                <count group_id="O3" value="181"/>
                <count group_id="O4" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sinus tachycardia : related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sinus tachycardia : unrelated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tachycardia : related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tachycardia : unrelated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Palpitations : related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Palpitations : unrelated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild pericardial effusion : related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild pericardial effusion : unrelated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroconversion by ELISA</title>
        <description>Seroconversion rate based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA). Seroconversion is defined as the appearance of antibody titers ≥ detection limit (50) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
        <time_frame>4 weeks following the last vaccination (Week 8 for Groups 1-3, Week 4 for Group 4)</time_frame>
        <population>Full Analysis Set (includes subjects with data available 4 weeks following the last vaccination)</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 2x MVA-BN® s.c., Vaccinia Naive</title>
            <description>vaccinia naive subjects receiving two subcutaneous vaccinations with 0.5mL MVA-BN® IMVAMUNE (1x10E08 TCID50)</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 1x MVA-BN®, 1x Placebo, s.c., Vaccinia Naive</title>
            <description>vaccinia naive subjects receiving one subcutaneous vaccination with 0.5mL MVA-BN® IMVAMUNE (1x10E08 TCID50), followed by one subcutaneous vaccination Placebo (0.5mL Tris Buffer)</description>
          </group>
          <group group_id="O3">
            <title>Group 3: 2x Placebo, s.c., Vaccinia Naive</title>
            <description>vaccinia naive subjects receiving two subcutaneous vaccinations with Placebo (0.5mL Tris Buffer)
Placebo: Tris-Buffer</description>
          </group>
          <group group_id="O4">
            <title>Group 4: 1x MVA-BN®, s.c., Vaccinia Experienced</title>
            <description>vaccinia experienced subjects receiving one subcutaneous vaccination with 0.5mL MVA-BN® IMVAMUNE (1x10E08 TCID50)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion by ELISA</title>
          <description>Seroconversion rate based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA). Seroconversion is defined as the appearance of antibody titers ≥ detection limit (50) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
          <population>Full Analysis Set (includes subjects with data available 4 weeks following the last vaccination)</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="175"/>
                <count group_id="O3" value="177"/>
                <count group_id="O4" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.9"/>
                    <measurement group_id="O2" value="72.0"/>
                    <measurement group_id="O3" value="2.8"/>
                    <measurement group_id="O4" value="93.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroconversion by PRNT</title>
        <description>Seroconversion rate based on vaccinia-specific Plaque Reduction Neutralization Test (PRNT). Seroconversion is defined as the appearance of antibody titers ≥ detection limit (6) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
        <time_frame>2 weeks following the last vaccination (Week 6 for Groups 1-3, Week 2 for Group 4)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 2x MVA-BN® s.c., Vaccinia Naive</title>
            <description>vaccinia naive subjects receiving two subcutaneous vaccinations with 0.5mL MVA-BN® IMVAMUNE (1x10E08 TCID50)</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 1x MVA-BN®, 1x Placebo, s.c., Vaccinia Naive</title>
            <description>vaccinia naive subjects receiving one subcutaneous vaccination with 0.5mL MVA-BN® IMVAMUNE (1x10E08 TCID50), followed by one subcutaneous vaccination Placebo (0.5mL Tris Buffer)</description>
          </group>
          <group group_id="O3">
            <title>Group 3: 2x Placebo, s.c., Vaccinia Naive</title>
            <description>vaccinia naive subjects receiving two subcutaneous vaccinations with Placebo (0.5mL Tris Buffer)
Placebo: Tris-Buffer</description>
          </group>
          <group group_id="O4">
            <title>Group 4: 1x MVA-BN®, s.c., Vaccinia Experienced</title>
            <description>vaccinia experienced subjects receiving one subcutaneous vaccination with 0.5mL MVA-BN® IMVAMUNE (1x10E08 TCID50)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion by PRNT</title>
          <description>Seroconversion rate based on vaccinia-specific Plaque Reduction Neutralization Test (PRNT). Seroconversion is defined as the appearance of antibody titers ≥ detection limit (6) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
          <population>Full Analysis Set</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="174"/>
                <count group_id="O3" value="175"/>
                <count group_id="O4" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.2"/>
                    <measurement group_id="O2" value="56.3"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="78.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroconversion by PRNT</title>
        <description>Seroconversion rate based on vaccinia-specific Plaque Reduction Neutralization Test (PRNT). Seroconversion is defined as the appearance of antibody titers ≥ detection limit (6) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
        <time_frame>4 weeks following the last vaccination (Week 8 for Groups 1-3, Week 4 for Group 4)</time_frame>
        <population>Full Analysis Set (includes subjects with data available 4 weeks following the last vaccination)</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 2x MVA-BN® s.c., Vaccinia Naive</title>
            <description>vaccinia naive subjects receiving two subcutaneous vaccinations with 0.5mL MVA-BN® IMVAMUNE (1x10E08 TCID50)</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 1x MVA-BN®, 1x Placebo, s.c., Vaccinia Naive</title>
            <description>vaccinia naive subjects receiving one subcutaneous vaccination with 0.5mL MVA-BN® IMVAMUNE (1x10E08 TCID50), followed by one subcutaneous vaccination Placebo (0.5mL Tris Buffer)</description>
          </group>
          <group group_id="O3">
            <title>Group 3: 2x Placebo, s.c., Vaccinia Naive</title>
            <description>vaccinia naive subjects receiving two subcutaneous vaccinations with Placebo (0.5mL Tris Buffer)
Placebo: Tris-Buffer</description>
          </group>
          <group group_id="O4">
            <title>Group 4: 1x MVA-BN®, s.c., Vaccinia Experienced</title>
            <description>vaccinia experienced subjects receiving one subcutaneous vaccination with 0.5mL MVA-BN® IMVAMUNE (1x10E08 TCID50)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion by PRNT</title>
          <description>Seroconversion rate based on vaccinia-specific Plaque Reduction Neutralization Test (PRNT). Seroconversion is defined as the appearance of antibody titers ≥ detection limit (6) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
          <population>Full Analysis Set (includes subjects with data available 4 weeks following the last vaccination)</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="175"/>
                <count group_id="O3" value="177"/>
                <count group_id="O4" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.0"/>
                    <measurement group_id="O2" value="47.4"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="69.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Related Serious Adverse Events</title>
        <description>Number of participants with any serious adverse event possibly, probably or definitely related to the study vaccine at any time during the study</description>
        <time_frame>within 32 weeks</time_frame>
        <population>Safety dataset</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 2x MVA-BN® s.c., Vaccinia Naive</title>
            <description>vaccinia naive subjects receiving two subcutaneous vaccinations with 0.5mL MVA-BN® IMVAMUNE (1x10E08 TCID50)</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 1x MVA-BN®, 1x Placebo, s.c., Vaccinia Naive</title>
            <description>vaccinia naive subjects receiving one subcutaneous vaccination with 0.5mL MVA-BN® IMVAMUNE (1x10E08 TCID50), followed by one subcutaneous vaccination Placebo (0.5mL Tris Buffer)</description>
          </group>
          <group group_id="O3">
            <title>Group 3: 2x Placebo, s.c., Vaccinia Naive</title>
            <description>vaccinia naive subjects receiving two subcutaneous vaccinations with Placebo (0.5mL Tris Buffer)
Placebo: Tris-Buffer</description>
          </group>
          <group group_id="O4">
            <title>Group 4: 1x MVA-BN®, s.c., Vaccinia Experienced</title>
            <description>vaccinia experienced subjects receiving one subcutaneous vaccination with 0.5mL MVA-BN® IMVAMUNE (1x10E08 TCID50)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Related Serious Adverse Events</title>
          <description>Number of participants with any serious adverse event possibly, probably or definitely related to the study vaccine at any time during the study</description>
          <population>Safety dataset</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="181"/>
                <count group_id="O3" value="181"/>
                <count group_id="O4" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Solicited Local Adverse Events</title>
        <description>Number of participants with solicited local AEs (pain, erythema, swelling and induration) within 8 days after any vaccination (vaccinations for Groups 1-3: Days 0 and 28; Group 4: Day 0). Percentages based on subjects with at least one completed diary card.</description>
        <time_frame>within 8 days after any vaccination</time_frame>
        <population>Safety dataset</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 2x MVA-BN® s.c., Vaccinia Naive</title>
            <description>vaccinia naive subjects receiving two subcutaneous vaccinations with 0.5mL MVA-BN® IMVAMUNE (1x10E08 TCID50)</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 1x MVA-BN®, 1x Placebo, s.c., Vaccinia Naive</title>
            <description>vaccinia naive subjects receiving one subcutaneous vaccination with 0.5mL MVA-BN® IMVAMUNE (1x10E08 TCID50), followed by one subcutaneous vaccination Placebo (0.5mL Tris Buffer)</description>
          </group>
          <group group_id="O3">
            <title>Group 3: 2x Placebo, s.c., Vaccinia Naive</title>
            <description>vaccinia naive subjects receiving two subcutaneous vaccinations with Placebo (0.5mL Tris Buffer)
Placebo: Tris-Buffer</description>
          </group>
          <group group_id="O4">
            <title>Group 4: 1x MVA-BN®, s.c., Vaccinia Experienced</title>
            <description>vaccinia experienced subjects receiving one subcutaneous vaccination with 0.5mL MVA-BN® IMVAMUNE (1x10E08 TCID50)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited Local Adverse Events</title>
          <description>Number of participants with solicited local AEs (pain, erythema, swelling and induration) within 8 days after any vaccination (vaccinations for Groups 1-3: Days 0 and 28; Group 4: Day 0). Percentages based on subjects with at least one completed diary card.</description>
          <population>Safety dataset</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="182"/>
                <count group_id="O2" value="179"/>
                <count group_id="O3" value="179"/>
                <count group_id="O4" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection site pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166"/>
                    <measurement group_id="O2" value="155"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166"/>
                    <measurement group_id="O2" value="146"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149"/>
                    <measurement group_id="O2" value="103"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162"/>
                    <measurement group_id="O2" value="146"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Solicited General Adverse Events</title>
        <description>Number of participants with solicited systemic/general AEs (body temperature increased, headache, myalgia, nausea, and fatigue) within 8 days after any vaccination (vaccinations for Groups 1-3: Days 0 and 28; Group 4: Day 0). Percentages based on subjects with at least one completed diary card.</description>
        <time_frame>within 8 days after any vaccination</time_frame>
        <population>Safety dataset</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 2x MVA-BN® s.c., Vaccinia Naive</title>
            <description>vaccinia naive subjects receiving two subcutaneous vaccinations with 0.5mL MVA-BN® IMVAMUNE (1x10E08 TCID50)</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 1x MVA-BN®, 1x Placebo, s.c., Vaccinia Naive</title>
            <description>vaccinia naive subjects receiving one subcutaneous vaccination with 0.5mL MVA-BN® IMVAMUNE (1x10E08 TCID50), followed by one subcutaneous vaccination Placebo (0.5mL Tris Buffer)</description>
          </group>
          <group group_id="O3">
            <title>Group 3: 2x Placebo, s.c., Vaccinia Naive</title>
            <description>vaccinia naive subjects receiving two subcutaneous vaccinations with Placebo (0.5mL Tris Buffer)
Placebo: Tris-Buffer</description>
          </group>
          <group group_id="O4">
            <title>Group 4: 1x MVA-BN®, s.c., Vaccinia Experienced</title>
            <description>vaccinia experienced subjects receiving one subcutaneous vaccination with 0.5mL MVA-BN® IMVAMUNE (1x10E08 TCID50)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited General Adverse Events</title>
          <description>Number of participants with solicited systemic/general AEs (body temperature increased, headache, myalgia, nausea, and fatigue) within 8 days after any vaccination (vaccinations for Groups 1-3: Days 0 and 28; Group 4: Day 0). Percentages based on subjects with at least one completed diary card.</description>
          <population>Safety dataset</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="182"/>
                <count group_id="O2" value="179"/>
                <count group_id="O3" value="179"/>
                <count group_id="O4" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Body temperature increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="84"/>
                    <measurement group_id="O3" value="49"/>
                    <measurement group_id="O4" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="55"/>
                    <measurement group_id="O4" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Related Grade&gt;=3 Adverse Events</title>
        <description>Number of participants with any Grade &gt;=3 AE probably, possibly, or definitely related to the study vaccine within 4 weeks after any vaccination (vaccinations for Groups 1-3: Days 0 and 28; Group 4: Day 0). Pooled solicited (local and general) and unsolicited AEs.</description>
        <time_frame>within 4 weeks after any vaccination</time_frame>
        <population>Safety dataset</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 2x MVA-BN® s.c., Vaccinia Naive</title>
            <description>vaccinia naive subjects receiving two subcutaneous vaccinations with 0.5mL MVA-BN® IMVAMUNE (1x10E08 TCID50)</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 1x MVA-BN®, 1x Placebo, s.c., Vaccinia Naive</title>
            <description>vaccinia naive subjects receiving one subcutaneous vaccination with 0.5mL MVA-BN® IMVAMUNE (1x10E08 TCID50), followed by one subcutaneous vaccination Placebo (0.5mL Tris Buffer)</description>
          </group>
          <group group_id="O3">
            <title>Group 3: 2x Placebo, s.c., Vaccinia Naive</title>
            <description>vaccinia naive subjects receiving two subcutaneous vaccinations with Placebo (0.5mL Tris Buffer)
Placebo: Tris-Buffer</description>
          </group>
          <group group_id="O4">
            <title>Group 4: 1x MVA-BN®, s.c., Vaccinia Experienced</title>
            <description>vaccinia experienced subjects receiving one subcutaneous vaccination with 0.5mL MVA-BN® IMVAMUNE (1x10E08 TCID50)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Related Grade&gt;=3 Adverse Events</title>
          <description>Number of participants with any Grade &gt;=3 AE probably, possibly, or definitely related to the study vaccine within 4 weeks after any vaccination (vaccinations for Groups 1-3: Days 0 and 28; Group 4: Day 0). Pooled solicited (local and general) and unsolicited AEs.</description>
          <population>Safety dataset</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="181"/>
                <count group_id="O3" value="181"/>
                <count group_id="O4" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Unsolicited Non-serious Adverse Events</title>
        <description>Number of participants with non-serious unsolicited AEs within 4 weeks after any vaccination (vaccinations for Groups 1-3: Days 0 and 28; Group 4: Day 0).</description>
        <time_frame>within 4 weeks after any vaccination</time_frame>
        <population>Safety dataset</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 2x MVA-BN® s.c., Vaccinia Naive</title>
            <description>vaccinia naive subjects receiving two subcutaneous vaccinations with 0.5mL MVA-BN® IMVAMUNE (1x10E08 TCID50)</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 1x MVA-BN®, 1x Placebo, s.c., Vaccinia Naive</title>
            <description>vaccinia naive subjects receiving one subcutaneous vaccination with 0.5mL MVA-BN® IMVAMUNE (1x10E08 TCID50), followed by one subcutaneous vaccination Placebo (0.5mL Tris Buffer)</description>
          </group>
          <group group_id="O3">
            <title>Group 3: 2x Placebo, s.c., Vaccinia Naive</title>
            <description>vaccinia naive subjects receiving two subcutaneous vaccinations with Placebo (0.5mL Tris Buffer)
Placebo: Tris-Buffer</description>
          </group>
          <group group_id="O4">
            <title>Group 4: 1x MVA-BN®, s.c., Vaccinia Experienced</title>
            <description>vaccinia experienced subjects receiving one subcutaneous vaccination with 0.5mL MVA-BN® IMVAMUNE (1x10E08 TCID50)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Unsolicited Non-serious Adverse Events</title>
          <description>Number of participants with non-serious unsolicited AEs within 4 weeks after any vaccination (vaccinations for Groups 1-3: Days 0 and 28; Group 4: Day 0).</description>
          <population>Safety dataset</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="181"/>
                <count group_id="O3" value="181"/>
                <count group_id="O4" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="106"/>
                    <measurement group_id="O3" value="78"/>
                    <measurement group_id="O4" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>32 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>GP 1: Two x 1x10E08 TCID, MVA-BN® s.c., Vaccinia Naive</title>
          <description>vaccinia naive subjects receiving two subcutanenous vaccinations with 0.5ml MVA-BN® IMVAMUNE (1x10E08 TCID)
MVA-BN® (IMVAMUNE): 1x 10E8_TCID50</description>
        </group>
        <group group_id="E2">
          <title>GP 2: 1x10E08 TCID, MVA-BN®, 1x Placebo, s.c., Vaccinia Naive</title>
          <description>vaccinica naive subjects receiving one vaccination with 0.5ml MVA-BN® IMVAMUNE(1x10E08 TCID), followed by one vaccination Placebo (0.5ml Tris Buffer)
MVA-BN® (IMVAMUNE): 1x 10E8_TCID50
Placebo: Tris-Buffer</description>
        </group>
        <group group_id="E3">
          <title>GP 3: Two x Placebo, s.c., Vaccinia Naive</title>
          <description>vaccinia naive subjects, receiving two subcutaneous vaccinations with Placebo (0.5ml Tris Buffer).
Placebo: Tris-Buffer</description>
        </group>
        <group group_id="E4">
          <title>GP 4: 1x10E08 TCID, MVA-BN®, s.c., Vaccinia Experienced</title>
          <description>vaccinia experienced subjects, receiving one subcutaneous vaccination with 0.5ml MVA-BN® IMVAMUNE (1x10E08 TCID).
MVA-BN® (IMVAMUNE): 1x 10E8_TCID50</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 7.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Thyroid cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Sarcoidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Tendon injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign neoplasm of thyroid gland</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Thyroidectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Tonsillectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 7.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="183"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="181"/>
                <counts group_id="E4" subjects_affected="73" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopaty</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="181"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="181"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="181"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" events="61" subjects_affected="43" subjects_at_risk="183"/>
                <counts group_id="E2" events="37" subjects_affected="36" subjects_at_risk="181"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="181"/>
                <counts group_id="E4" events="49" subjects_affected="49" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Injection site hematoma</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="183"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="181"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="181"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Injection site warmth</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="183"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Injection site discoloration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="181"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="45" subjects_affected="42" subjects_at_risk="183"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="181"/>
                <counts group_id="E3" events="28" subjects_affected="26" subjects_at_risk="181"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="181"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Tonsilitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="181"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="181"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="183"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="181"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="181"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="181"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="183"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="181"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="183"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="181"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="181"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Program Lead, Clinical Operations</name_or_title>
      <organization>Bavarian Nordic A/S</organization>
      <phone>+45 3326 ext 8383</phone>
      <email>info@bavarian-nordic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

